

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
1	20/YH/0177	273999	The effect of increased sodium intake with a carbohydrate-rich meal on glucose homeostasis in subjects without diabetes after bariatric surgery.	No					06/02/2020	07/05/2020	29/06/2020		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
2	20/SC/0153	271051	Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial.	No					24/03/2020	12/05/2020	26/10/2020		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
3	18/SC/0580	235355	FROSTTIE: A randomised controlled trial of Frenotomy and breastfeeding support Or breastfeeding Support without frenotomy to investigate continuation of breastfeeding for babies with Tongue-TIE	No		157			19/02/2020	02/06/2020	19/12/2018	27/08/2020	06/11/2020	Please Select...		A - Permissions delayed/denied C - Closed by sponsor	Study abandoned by sponsor , Sponsor permission delay	Sponsor
4	20/YH/0123	263968	The effect of Canagliflozin 300mg in subjects without diabetes after bariatric surgery, on glucose homeostasis (CONTROL): A proof-of-concept, randomised, open-label, two period crossover study.	No					11/09/2019	04/06/2020	01/06/2020	19/03/2021		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
5	20/WM/0153	282437	The efficacy and feasibility of face mask sampling for hospitalised adult patients and healthcare workers with suspected COVID-19	No		5			12/05/2020	04/06/2020	02/06/2020	09/06/2020	09/06/2020	Please Select...	10/06/2020	G - No patients consented	Screening going on, No Suitable patients	Neither
6	20/WM/0117	276905	Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: a randomised controlled trial	No					29/01/2020	10/06/2020	02/06/2020	01/09/2020		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
7	19/NW/0135	252254	An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	Yes	28/04/2021	61	210	271	01/07/2019	31/07/2020	17/05/2019	02/10/2020	30/09/2020	Please Select...	12/10/2020	A - Permissions delayed/denied D - Sponsor Delays G - No patients consented	Sponsor permission delay, Screening going on, No Suitable patients	Sponsor
8	19/SC/0622	270469	A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma	No		20			19/08/2019	06/08/2020	14/02/2020	26/08/2020	26/08/2020	Please Select...	08/12/2020	G - No patients consented	Screening going on, No Suitable patients ,	Neither
9	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	No		77			20/12/2019	11/08/2020	03/04/2020	09/09/2020	27/10/2020	Please Select...	02/11/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay, Screening	Sponsor

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
																G - No patients consented		
10	19/WM/0364	257918	Letrozole or Clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome: a 2x2 factorial design randomised trial (The LOCI trial)	No					24/02/2020	14/08/2020	09/06/2020		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
11	18/SC/0015	236685	A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	Yes	19/04/2021	0	216	216	01/05/2019	15/09/2020	23/02/2018	02/09/2020	15/09/2020	Please Select...	28/09/2020	G - No patients consented	Screening going on, No Suitable patients	Neither
12	20/EM/0162	280970	Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma	No					09/09/2020	09/09/2020	28/10/2020		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
13	20/YH/0232	280105	ATNEC?Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEOadjuvant Chemotherapy	No					09/03/2020	18/09/2020	22/10/2020		Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor	
14	18/WA/0239	243333	Determining the Effectiveness of early Intensive Versus Escalation approaches for the treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)	No		68			05/03/2020	23/09/2020	21/12/2018	16/11/2020	30/11/2020	Please Select...		A - Permissions delayed/denied D - Sponsor Delays G - No patients consented	Sponsor permission delay, Screening going on, No Suitable patients	Sponsor
15	19/YH/0380	273434	A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Ceftazidime Avibactam (CAZ-AVI) in Children From 3 Months to Less Than 18 Years of Age Who are Hospitalized and Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia	No		44			01/04/2019	23/09/2020	25/02/2020	25/09/2020	06/11/2020	Please Select...		A - Permissions delayed/denied D - Sponsor Delays G - No patients consented	Screening going on, No Suitable patients, Sponsor permission delay	Sponsor
16	19/WM/0251	264348	Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia	Yes	12/04/2021	9	178	187	01/08/2019	07/10/2020	07/11/2019	19/11/2020	16/10/2020	Please Select...	29/01/2021	G - No patients consented	Screening going on, No Suitable patients	Neither

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
17	20/WA/0098	275346	Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy	No		17			05/09/2019	12/10/2020	29/04/2020	06/10/2020	29/10/2020	Please Select...	30/10/2020	G - No patients consented	Screening going on, No Suitable patients	Neither
18	17/LO/0054	199080	Prospective randomised trial of digital breast tomosynthesis (DBT) plus standard 2D digital mammography (2DDM) or synthetic 2D mammography (S 2D) compared to standard 2D digital mammography in breast cancer screening.	No					15/10/2020	15/10/2020	13/02/2017			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
19	19/LO/0408	257662	PROMISE UK: Percutaneous Deep Vein Arterialization with the Limflow System	No		145			10/09/2020	22/10/2020	03/05/2019	08/03/2021	16/03/2021	Please Select...	17/03/2021	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
20	19/SC/0634	252084	Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial)	No					23/01/2020	28/10/2020	04/08/2020			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
21	20/NW/0169	278290	Nasal High-Flow Oxygen Therapy After Cardiac Surgery (NOTACS) Study: Effect of High-Flow Nasal Therapy on Patient-Centred Outcomes in Patients at High Risk of Postoperative Pulmonary Complications After Cardiac Surgery: A Multicentre Randomised Controlled Trial.	No					26/03/2020	30/10/2020	19/06/2020			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay due to covid	Sponsor
22	20/WS/0062	256875	A multicomponent physical activity programme for women who have been treated for cervical cancer: A feasibility study	Yes	28/10/2020	123	23	146	20/05/2020	04/06/2020	20/05/2020	06/08/2020	05/10/2020	Please Select...	21/10/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
23	20/LO/0639	281304	A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.	Yes	13/04/2021	33	112	145	05/11/2019	19/11/2020	01/06/2020	21/12/2020	22/12/2020	Please Select...	22/12/2020	G - No patients consented	Screening going on, No Suitable patients	Neither
24	20/NI/0131	278283	A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT	No		23			13/08/2020	25/11/2020	21/10/2020	07/12/2020	18/12/2020	Please Select...	05/01/2021	G - No patients consented	Screening going on, No Suitable patients	Neither
25	20/SC/0433	282917	Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over	No					30/10/2020	26/11/2020	05/01/2020			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
26	20/NE/0171	279531	A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)	No		35			01/12/2020	10/12/2020	04/09/2020	18/12/2020	14/01/2021	Please Select...	14/01/2021	G - No patients consented	Screening going on, No Suitable patients	Neither

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
27	20/NW/0183	1003230	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When added to Background Care for the Treatment of Calciphylaxis.	No		11			29/01/2020	10/12/2020	21/05/2020	15/12/2020	21/12/2020	Please Select...	21/01/2021	G - No patients consented	Screening going on, No Suitable patients	Neither
28	20/ES/0122	1003500	Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort? UD in Ocular Hypertensive or Glaucomatous Patients	No					17/11/2020	17/12/2020	01/02/2021			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
29	20/NW/0381	1003380	A Randomised, Open-Label, Parallel-Group, Pre surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer	No					11/12/2020	21/12/2020	16/11/2020			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
30	20/LO/1102	281671	RESPONSE - Breaking up prolonged sitting in people with type 2 diabetes: Optimising the response..	No		31			09/06/2020	21/12/2020	19/11/2020	07/01/2021	21/01/2021	Please Select...	08/03/2021	G - No patients consented	Screening going on, No Suitable patients	Neither
31	19/NE/0145	254931	FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma	No		22			05/02/2019	30/12/2020	22/07/2019	08/01/2021	21/01/2021	Please Select...	12/02/2021	G - No patients consented	Screening going on, No Suitable patients	Neither
32	19/SC/0416	269256	A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)	Yes	08/10/2020	42	45	87	16/04/2020	13/07/2020	04/10/2019	11/08/2020	24/08/2020	Please Select...	01/10/2020	A - Permissions delayed/denied D - Sponsor Delays G - No patients consented	Screening going on, No Suitable patients , Sponsor permission delay	Sponsor
33	19/LO/1633	271207	ADAPT - Advanced Hybrid Closed Loop study in Adult Population with Type 1 Diabetes	No		42			08/12/2020	12/01/2021	31/12/2019	10/02/2021	23/02/2021	Please Select...	26/02/2021	A - Permissions delayed/denied D - Sponsor Delays G - No patients consented	Sponsor permission delay,Screening going	Sponsor
34	20/ES/0031	276439	Protocol I8F-MC-GPGN The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)	Yes	18/11/2020	53	23	76	17/02/2020	03/09/2020	30/09/2020	21/10/2020	26/10/2020	Please Select...	05/11/2020	A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
35	20/WS/0070	275797	A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction =40% (LVEF= 40%).	No					21/04/2020	19/01/2021	04/06/2020			Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
36	19/EE/0174	255746	The third Multi-Centre Intra-Pleural Sepsis Trial (MIST-3): Early Video Assisted Thoracoscopic Surgery (VATS) or Intrapleural Enzyme Therapy (IET) in Pleural infection - a feasibility, randomised trial	Yes	04/12/2020	33	38	71	24/09/2020	24/09/2020	30/07/2019	23/10/2020	27/10/2020	Please Select...	27/10/2020		0	Please Select...
37	20/EM/0081	276533	A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma.	No		54			09/01/2020	21/01/2021	30/11/2020	15/03/2021	16/03/2021	Please Select...		A - Permissions delayed/denied D - Sponsor Delays	Sponsor permission delay	Sponsor
38	20/SS/0057	281986	STOP-COVID19	Yes	13/07/2020	38	31	69	05/05/2020	05/05/2020	22/05/2020	05/06/2020	12/06/2020	Please Select...	09/07/2020		0	Please Select...
39	20/SC/0201	282769	ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients	Yes	08/07/2020	12	57	69	29/04/2020	30/04/2020	28/04/2020	07/05/2020	12/05/2020	Please Select...	19/05/2020		0	Please Select...

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
40	19/NE/0215	234453	Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).	Yes	16/12/2020	1	68	69	01/05/2018	08/10/2020	07/11/2019	28/10/2020	09/10/2020	Please Select...	29/10/2020		0	Please Select...
41	20/YH/0339	282343	The impact of a fat rich preload before a carbohydrate-rich meal on glucose homeostasis in patients without diabetes after sleeve gastrectomy: A proof-of-concept, randomised, open-label, crossover study	No					15/07/2020	26/01/2021	26/01/2021	28/01/2021		Please Select...		A - Permissions delayed/denied	Sponsor permission delay	Sponsor
42	20/EM/0068	274507	Daily intake of Lactobacillus casei Shirota (LcS) modulates intestinal permeability and decreases circulating levels of endotoxin that associate with both cardiovascular and all-cause mortality in haemodialysis (HD) patients.	Yes	28/10/2020	20	44	64	18/12/2019	25/08/2020	03/04/2020	03/09/2020	14/09/2020	Please Select...	21/09/2020		0	Please Select...
43	20/SC/0111	276734	DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma	Yes	23/11/2020	0	63	63	11/12/2019	21/09/2020	12/05/2020	08/09/2020	21/09/2020	Please Select...	22/09/2020		0	Please Select...
44	20/LO/0223	274833	A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	No		7			26/02/2020	28/01/2021	11/06/2020	04/12/2020	04/02/2021	Please Select...	01/03/2021	G - No patients consented	Screening going on, No Suitable patients	Neither
45	20/LO/1090	288214	A Phase 1, First in Human (FIH), Dose Escalation Study of JNJ-74856665 (dihydroorotate dehydrogenase [DHODH] Inhibitor) in Participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	No		1			18/09/2021	03/02/2021	23/10/2020	28/01/2021	04/02/2021	Please Select...	08/02/2021			Please Select...
46	19/EE/0362	272768	A Randomised Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children (Oxy-PICU)	Yes	16/10/2020	21	31	52	11/08/2020	25/08/2020	23/12/2019	04/09/2020	15/09/2020	Please Select...	15/09/2020			Please Select...
47	20/NE/0092	277972	AN OPEN-LABEL, PHASE I STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF RO7227166 (A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND INCOMBINATION WITH RO7082859 (CD20-TCB) FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA	Yes	25/08/2020	22	26	48	06/03/2020	08/07/2020	05/05/2020	27/07/2020	30/07/2020	Please Select...	30/07/2020			Please Select...
48	20/SC/0189	278270	A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2)	Yes	08/12/2020	16	26	42	27/10/2020	27/10/2020	10/07/2020	29/10/2020	12/11/2020	Please Select...	20/11/2020			Please Select...

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
49	18/SC/0634	233709	STELLAR: A phase II, randomised study of CHOP-R in combination with acalabrutinib compared to CHOP-R in patients with newly diagnosed Richter's Syndrome (RS) and a pLAtfoRm for initial investigations into activity of novel treatments in relapsed/refractory and newly diagnosed RS.	Yes	08/09/2020	20	19	39	02/08/2019	31/07/2020	31/01/2019	06/08/2020	20/08/2020	Please Select...	02/09/2020			Please Select...
50	20/HRA/5234	290965	A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19	Yes	16/02/2021	13	21	34	13/01/2021	13/01/2021	09/11/2020	26/01/2021	26/01/2021	Please Select...	26/01/2021			Please Select...
51	21/FT/0038	288581	A phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate to severe chronic hand eczema (DELTA 1)	No					08/10/2020	04/03/2021	15/03/2021			Please Select...				Please Select...
52	20/NE/0253	288479	COVID-NURSE: evaluation of the effects of a COVID-specific fundamental nursing care protocol compared to care as usual on experience of care for non-invasively ventilated patients in hospital with the SARS-CoV-2 virus: a randomised controlled trial.	No		11			05/10/2020	05/03/2021	11/11/2020	04/02/2021	16/03/2021	Please Select...				Please Select...
53	20/LO/1059	287861	An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of IMP Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301	No					14/07/2020	09/03/2021	23/11/2020			Please Select...				Please Select...
54	20/LO/0944	1003371	SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer	No					24/02/2021	15/03/2021	27/08/2020	31/03/2021		Please Select...				Please Select...
55	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	Yes	23/04/2020	11	3	14	08/04/2020	09/04/2020	03/04/2020	20/04/2020	20/04/2020	Please Select...	21/04/2020			Please Select...
56	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Yes	25/11/2020	9	4	13	08/10/2020	12/11/2020	10/11/2020	20/11/2020	21/11/2020	Please Select...	21/11/2020			Please Select...
57	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	Yes	04/05/2020	5	6	11	07/04/2020	23/04/2020	23/07/2018	23/04/2020	28/04/2020	Please Select...	29/04/2020			Please Select...
58	20/LO/0848	272164	ALLTogether1? A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)	No					17/09/2020	23/03/2021	25/01/2021			Please Select...				Please Select...
59	20/SC/0365	1003436	A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant/Adjuvant Durvalumab and Standard Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC)	No					21/08/2020	26/03/2021	13/11/2020			Please Select...				Please Select...
60	20/WM/0054	264593	CRAFFT ? Children's Radius - Acute Fracture Fixation Trial: A multi-centre prospective randomised non-inferiority trial of surgical reduction versus non-surgical casting for displaced distal radius fractures in children.	No					14/10/2020	30/03/2021	16/04/2020			Please Select...				Please Select...